After joining the ICH, the NMPA had provided strong policy support in the whole life cycle of Novel Therapies Approval, Clinical Trials, Manufacturing and Subsequent Marketing. These new  drug R&D policies have enabled China's innovative drug R&D and production capabilities to make tremendous progress. BIC 2022 will focusing on topics of innovative drug development and processes,  ICH Reforming Innovation, Continuous Manufacturing, ADCs, BiAbs Development, Cell&Gene Therapy, Stem Cell Therapy, Oncolytic Viruses, mRNA Vaccines, Innovation Upstream and Downstream Processing, Continuous Bioprocessing, Single Use Technology, Biomanufacturing 4.0, Packaging, QbD, Quality Control, Characterization Analysis and etc.

BIC 2022 will gather 4000+ attendees, 150+ speakers, 120+ exhibitors and 500+ organizations from the globe.